1. A Pharmacokinetic and Safety Study of Trebananib, an Fc‐Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction. Issue 2 (9th June 2017) Authors: Wu, B; Lewis, LD; Harvey, RD; Rasmussen, E; Gamelin, E; Sun, Y‐N; Friberg, G; Koyner, JL; Dowlati, A; Maitland, ML Journal: Clinical pharmacology & therapeutics Issue: Volume 102:Issue 2(2017) Page Start: 313 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Exploratory Modeling and Simulation to Support Development of Motesanib in Asian Patients With Non–Small Cell Lung Cancer Based on MONET1 Study Results. Issue 4 (17th January 2014) Authors: Claret, L; Bruno, R; Lu, J‐F; Sun, Y‐N; Hsu, C‐P Journal: Clinical pharmacology & therapeutics Issue: Volume 95:Issue 4(2014) Page Start: 446 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab‐Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity. (22nd August 2015) Authors: Xu, Y; Hijazi, Y; Wolf, A; Wu, B; Sun, Y‐N; Zhu, M Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 4:Number 9(2015:Sep.) Page Start: 507 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗